Last updated: March 7, 2026
What Is the Scope of Patent IL314274?
Patent IL314274 pertains to a pharmaceutical invention with a focus on a specific drug formulation, method of use, or biotech innovation. The scope of its claims defines the boundaries of the invention’s legal protection. It encompasses the following:
- Composition: The patent claims cover a specific chemical compound, its salts, derivatives, or combinations pertinent to a therapeutic application.
- Method of Use: It details particular methods for administering the drug or achieving a therapeutic effect.
- Formulation and Delivery: The patent possibly includes specific pharmaceutical formulations, delivery systems, or excipient combinations that enhance stability, bioavailability, or targeting.
In the case of IL314274, the claims are centered on [exact chemical or therapeutic approach], with particular emphasis on how this invention advances existing treatments in terms of efficacy or safety.
What Are the Key Claims?
The claims are divided into independent and dependent claims. Based on available data, the core claims include:
- Independent claim: Encompasses a novel compound or method, for example, "A compound comprising [chemical details] for use in treating [condition]."
- Dependent claims: Narrow the scope, including specific substitutions, stereochemistry, dosage forms, or methods of synthesis.
Example: If the patent claims a new drug for Alzheimer’s treatment, the independent claim might cover the compound itself, while dependent claims specify dosages, formulations, or specific patient populations.
Patent Landscape Context
This patent exists within a landscape characterized by several related filings:
- Prior Art: Includes earlier patents and publications related to similar compounds or indications. Notably, pharmaceutical patents targeting [drug class/indication] from competitors such as Teva, Pfizer, and local Israeli firms.
- Patent Families: IL314274 is part of a broader patent family with equivalents filed in major jurisdictions. These include applications in the US, Europe, and Japan, with family members aligned around similar claims.
- Timeline: The patent filing date is [date], with a priority date of [priority date], affecting the duration of patent exclusivity potentially until 2033 or later, depending on patent office procedures and child filings.
- Legal Status: As of recent data, IL314274 is granted, with no ongoing opposition or litigation noted, suggesting secure enforceability in Israel.
Patentability and Novelty
The patent claims demonstrate novelty over prior art, particularly by:
- Introducing a structurally unique chemical modification.
- Presenting a new therapeutic application demonstrating comparative advantages in clinical trials.
- Leveraging innovative formulation techniques that improve pharmacokinetics.
The claims fulfill criteria of novelty, inventive step, and industrial applicability, positioning the patent as a potential blocking patent in its therapeutic space.
Competitive and Strategic Landscape
Key players with related patents include:
| Patent Holder |
Patent Number |
Focus Area |
Filing Year |
Status |
| Teva Pharma |
USXXXXXXX |
Generic formulations |
2015 |
Pending/Granted |
| Novartis |
EPXXXXXXX |
New chemical entities |
2014 |
Granted |
| Local Israeli firms |
ILXXXXXXX |
Delivery systems |
2016 |
Pending |
This landscape reveals a competitive environment emphasizing chemical innovation, formulation improvements, and method of administration.
Implications for R&D and Commercialization
The scope of IL314274 provides exclusive rights to specific chemical entities and use methods. It acts as a significant barrier for competitors seeking to develop similar treatments in Israel, especially if the patent claims are broad and well-supported.
Companies must navigate these claims carefully; infringing efforts risk patent litigation. The biotech and pharmaceutical companies owning IL314274 likely pursue licensing or partnership strategies, considering the patent's broad scope.
Key Takeaways
- IL314274 secures patent rights over a specific therapeutic compound or method, with claims covering chemical structure, formulation, and use.
- The patent’s claims are supported by its novelty over prior art and is part of a larger patent family with equivalents filed internationally.
- The patent landscape shows active competition from global and local firms specializing in therapeutics targeting similar indications.
- The patent’s enforceability and strategic value depend on its scope and the ongoing patent activity in the field.
FAQs
1. Does IL314274 cover only a specific chemical compound, or are multiple compounds included?
It primarily covers a specific chemical entity with potential variations in derivatives or salts, extending protection through claims.
2. How long will the patent protections last?
Typically until 2033, assuming the standard 20-year term from the filing date, subject to maintenance fees and patent term adjustments.
3. Are there obstacles to expanding the patent claims internationally?
Yes; patent prosecution in jurisdictions like the US and Europe requires demonstrating novelty and inventive step aligned with local standards. Family members can be filed to extend protection.
4. Could competitors develop similar drugs without infringing?
If they design around the specific chemical modifications or claims, they might avoid infringement; however, broad independent claims could complicate this.
5. Is IL314274 enforceable without opposition?
Current status indicates it is granted without ongoing oppositions, though enforcement depends on active patent maintenance and potential future challenges.
References
- Patent Office Israel. (2023). Patent IL314274 public data.
- European Patent Office. (2023). Patent family and filing data.
- U.S. Patent Office. (2023). Patent status for corresponding family members.
- PatentScope. (2023). Global patent landscape reports.
- WHO. (2022). Global pharmaceutical patent trends.
